• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于小鼠和大鼠生物制品的计算机组装跨物种/跨模态双孔生理药代动力学模型

Computer-assembled cross-species/cross-modalities two-pore physiologically based pharmacokinetic model for biologics in mice and rats.

作者信息

Sepp Armin, Meno-Tetang Guy, Weber Andrew, Sanderson Andrew, Schon Oliver, Berges Alienor

机构信息

Systems Modeling and Translational Biology, 1F307 Glaxo Medicines Research Centre, GlaxoSmithKline, Stevenage, SG1 2NY, UK.

Clinical Pharmacology, Modelling and Simulation, GlaxoSmithKline, Stockley Park, Uxbridge, UB11 1BT, UK.

出版信息

J Pharmacokinet Pharmacodyn. 2019 Aug;46(4):339-359. doi: 10.1007/s10928-019-09640-9. Epub 2019 May 11.

DOI:10.1007/s10928-019-09640-9
PMID:31079322
Abstract

Two-pore physiologically-based pharmacokinetic (PBPK) models can be expected to describe the tissue distribution and elimination kinetics of soluble proteins, endogenous or dosed, as function of their size. In this work, we amalgamated our previous two-pore PBPK model for an inert domain antibody (dAb) in mice with the cross-species platform PBPK model for monoclonal antibodies described in literature into a unified two-pore platform that describes protein modalities of different sizes and includes neonatal Fc receptor (FcRn) mediated recycling. This unified PBPK model was parametrized for organ-specific lymph flow rates and the endosomal recycling rate constant using an extended tissue distribution time-course dataset that included an inert dAb, albumin and IgG in rats and mice. The model was evaluated by comparing the ab initio predictions for the tissue distribution and elimination properties of albumin-binding dAbs (AlbudAbs) in mice and rats with the experimental observations. Due to the large number of molecular species and reactions involved in large-scale PBPK models, we have also developed and deployed a Matlab script for automating the assembly of SimBiology-based two-pore biologics PBPK models which drastically cuts the time and effort required for model building.

摘要

基于生理的双孔药代动力学(PBPK)模型有望根据可溶性蛋白质(内源性或给药的)大小来描述其组织分布和消除动力学。在这项工作中,我们将之前针对小鼠体内惰性结构域抗体(dAb)的双孔PBPK模型与文献中描述的单克隆抗体跨物种平台PBPK模型合并为一个统一的双孔平台,该平台可描述不同大小的蛋白质形式,并包括新生儿Fc受体(FcRn)介导的循环利用。利用一个扩展的组织分布时程数据集(其中包括大鼠和小鼠体内的惰性dAb、白蛋白和IgG),针对器官特异性淋巴流速和内体循环速率常数对这个统一的PBPK模型进行了参数化。通过将小鼠和大鼠体内白蛋白结合dAb(AlbudAbs)的组织分布和消除特性的从头预测结果与实验观察结果进行比较,对该模型进行了评估。由于大规模PBPK模型涉及大量分子种类和反应,我们还开发并部署了一个Matlab脚本,用于自动组装基于SimBiology的双孔生物制剂PBPK模型,这大大减少了模型构建所需的时间和精力。

相似文献

1
Computer-assembled cross-species/cross-modalities two-pore physiologically based pharmacokinetic model for biologics in mice and rats.用于小鼠和大鼠生物制品的计算机组装跨物种/跨模态双孔生理药代动力学模型
J Pharmacokinet Pharmacodyn. 2019 Aug;46(4):339-359. doi: 10.1007/s10928-019-09640-9. Epub 2019 May 11.
2
Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.基于生理的药代动力学(PBPK)模型,用于预测野生型和FcRn基因敲除小鼠体内IgG的组织动力学。
J Pharmacokinet Pharmacodyn. 2007 Oct;34(5):687-709. doi: 10.1007/s10928-007-9065-1. Epub 2007 Jul 18.
3
Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.建立一个 PBPK 平台模型以描述单克隆抗体在临床前物种和人体内的血浆和组织分布特征。
J Pharmacokinet Pharmacodyn. 2012 Feb;39(1):67-86. doi: 10.1007/s10928-011-9232-2. Epub 2011 Dec 6.
4
Evaluation of a catenary PBPK model for predicting the in vivo disposition of mAbs engineered for high-affinity binding to FcRn.评估一个用于预测高亲和力结合 FcRn 的 mAbs 体内处置的悬链线 PBPK 模型。
AAPS J. 2012 Dec;14(4):850-9. doi: 10.1208/s12248-012-9395-9. Epub 2012 Sep 7.
5
A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim.PK-Sim 中治疗性蛋白的通用全身生理药代动力学模型。
J Pharmacokinet Pharmacodyn. 2018 Apr;45(2):235-257. doi: 10.1007/s10928-017-9559-4. Epub 2017 Dec 12.
6
Are endosomal trafficking parameters better targets for improving mAb pharmacokinetics than FcRn binding affinity?内体运输参数是否比 FcRn 结合亲和力更能成为改善单抗药代动力学的目标?
Mol Immunol. 2013 Dec;56(4):660-74. doi: 10.1016/j.molimm.2013.05.008. Epub 2013 Aug 2.
7
Translational two-pore PBPK model to characterize whole-body disposition of different-size endogenous and exogenous proteins.用于描述不同大小的内源性和外源性蛋白质在体内整体分布的双孔跨膜蛋白 PBPK 模型的转化。
J Pharmacokinet Pharmacodyn. 2024 Oct;51(5):449-476. doi: 10.1007/s10928-024-09922-x. Epub 2024 May 1.
8
Cross-species/cross-modality physiologically based pharmacokinetics for biologics: 89Zr-labelled albumin-binding domain antibody GSK3128349 in humans.跨物种/跨模态基于生理学的生物药剂学:在人体中 89Zr 标记的白蛋白结合结构域抗体 GSK3128349。
MAbs. 2020 Jan-Dec;12(1):1832861. doi: 10.1080/19420862.2020.1832861.
9
A Minimal Physiologically Based Pharmacokinetic Model with a Nested Endosome Compartment for Novel Engineered Antibodies.一种具有嵌套内体隔室的最小生理基于药代动力学模型,用于新型工程抗体。
AAPS J. 2018 Mar 14;20(3):48. doi: 10.1208/s12248-017-0183-4.
10
Model-Based Assessment of the Contribution of Monocytes and Macrophages to the Pharmacokinetics of Monoclonal Antibodies.基于模型的对单核细胞和巨噬细胞在单克隆抗体药代动力学中作用的评估。
Pharm Res. 2022 Feb;39(2):239-250. doi: 10.1007/s11095-022-03177-2. Epub 2022 Feb 3.

引用本文的文献

1
A multiscale physiologically based pharmacokinetic model to support mRNA-encoded BiTE therapy in cancer treatment.一种基于生理的多尺度药代动力学模型,以支持mRNA编码的双特异性T细胞衔接器(BiTE)疗法用于癌症治疗。
Mol Ther Nucleic Acids. 2025 Jun 16;36(3):102606. doi: 10.1016/j.omtn.2025.102606. eCollection 2025 Sep 9.
2
Cross-species translational modelling of targeted therapeutic oligonucleotides using physiologically based pharmacokinetics.使用基于生理学的药代动力学对靶向治疗性寡核苷酸进行跨物种翻译建模。
J Pharmacokinet Pharmacodyn. 2025 Jun 12;52(4):35. doi: 10.1007/s10928-025-09980-9.
3
Accelerating Biologics PBPK Modelling with Automated Model Building: A Tutorial.

本文引用的文献

1
A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim.PK-Sim 中治疗性蛋白的通用全身生理药代动力学模型。
J Pharmacokinet Pharmacodyn. 2018 Apr;45(2):235-257. doi: 10.1007/s10928-017-9559-4. Epub 2017 Dec 12.
2
Next generation antibody drugs: pursuit of the 'high-hanging fruit'.下一代抗体药物:追求“高挂的果实”。
Nat Rev Drug Discov. 2018 Mar;17(3):197-223. doi: 10.1038/nrd.2017.227. Epub 2017 Dec 1.
3
Interstitial IgG antibody pharmacokinetics assessed by combined in vivo- and physiologically-based pharmacokinetic modelling approaches.
通过自动模型构建加速生物制品的生理药代动力学(PBPK)建模:教程
Pharmaceutics. 2025 May 2;17(5):604. doi: 10.3390/pharmaceutics17050604.
4
The physiological limits of bispecific monoclonal antibody tissue targeting specificity.双特异性单克隆抗体组织靶向特异性的生理极限
MAbs. 2025 Dec;17(1):2492236. doi: 10.1080/19420862.2025.2492236. Epub 2025 Apr 13.
5
The role of automation in enhancing reproducibility and interoperability of PBPK models.自动化在提高生理药代动力学(PBPK)模型的可重复性和互操作性方面的作用。
Brief Bioinform. 2024 Nov 22;26(1). doi: 10.1093/bib/bbaf053.
6
Response to Letter to Editor by A. Derbalah et al.: the role of automation in enhancing reproducibility and interoperability of PBPK models.对A. Derbalah等人致编辑信的回复:自动化在提高生理药代动力学(PBPK)模型的可重复性和互操作性方面的作用。
Brief Bioinform. 2024 Nov 22;26(1). doi: 10.1093/bib/bbaf060.
7
Application of quantitative protein mass spectrometric data in the early predictive analysis of membrane-bound target engagement by monoclonal antibodies.定量蛋白质质谱数据在单克隆抗体膜结合靶点结合早期预测分析中的应用。
MAbs. 2024 Jan-Dec;16(1):2324485. doi: 10.1080/19420862.2024.2324485. Epub 2024 Mar 4.
8
Translational two-pore PBPK model to characterize whole-body disposition of different-size endogenous and exogenous proteins.用于描述不同大小的内源性和外源性蛋白质在体内整体分布的双孔跨膜蛋白 PBPK 模型的转化。
J Pharmacokinet Pharmacodyn. 2024 Oct;51(5):449-476. doi: 10.1007/s10928-024-09922-x. Epub 2024 May 1.
9
Biodistribution of Drug/ADA Complexes: The Impact of Immune Complex Formation on Antibody Distribution.药物/ADA 复合物的生物分布:免疫复合物形成对抗体分布的影响。
AAPS J. 2024 Mar 13;26(2):33. doi: 10.1208/s12248-024-00899-6.
10
Impact of tissue penetration and albumin binding on design of T cell targeted bispecific agents.组织穿透性和白蛋白结合对 T 细胞靶向双特异性抗体药物设计的影响。
Neoplasia. 2024 Feb;48:100962. doi: 10.1016/j.neo.2023.100962. Epub 2024 Jan 5.
采用体内与基于生理的药代动力学模型相结合的方法评估间质 IgG 抗体的药代动力学。
J Physiol. 2017 Dec 15;595(24):7311-7330. doi: 10.1113/JP274819. Epub 2017 Oct 29.
4
Cell surface dynamics and cellular distribution of endogenous FcRn.内源性新生Fc受体的细胞表面动力学和细胞分布
PLoS One. 2017 Aug 17;12(8):e0182695. doi: 10.1371/journal.pone.0182695. eCollection 2017.
5
Quantification of IgG monoclonal antibody clearance in tissues.组织中IgG单克隆抗体清除率的定量分析。
MAbs. 2017 Aug/Sep;9(6):1007-1015. doi: 10.1080/19420862.2017.1337619. Epub 2017 Jun 14.
6
Distribution of FcRn Across Species and Tissues.FcRn在不同物种和组织中的分布。
J Histochem Cytochem. 2017 Jun;65(6):321-333. doi: 10.1369/0022155417705095. Epub 2017 Apr 12.
7
Recent advances in (therapeutic protein) drug development.(治疗性蛋白质)药物研发的最新进展。
F1000Res. 2017 Feb 7;6:113. doi: 10.12688/f1000research.9970.1. eCollection 2017.
8
Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice.人新生儿Fc受体(FcRn)在Tg32转基因小鼠中的组织表达谱。
MAbs. 2016 Jul;8(5):848-53. doi: 10.1080/19420862.2016.1178436. Epub 2016 Apr 22.
9
Modeling bispecific monoclonal antibody interaction with two cell membrane targets indicates the importance of surface diffusion.对双特异性单克隆抗体与两个细胞膜靶点相互作用进行建模表明了表面扩散的重要性。
MAbs. 2016 Jul;8(5):905-15. doi: 10.1080/19420862.2016.1178437. Epub 2016 Apr 20.
10
Quantitative Analysis of Human Neonatal Fc Receptor (FcRn) Tissue Expression in Transgenic Mice by Online Peptide Immuno-Affinity LC-HRMS.通过在线肽免疫亲和液相色谱-高分辨率质谱法对转基因小鼠中人新生儿Fc受体(FcRn)组织表达进行定量分析。
Anal Chem. 2016 Apr 19;88(8):4239-47. doi: 10.1021/acs.analchem.5b03900. Epub 2016 Apr 4.